BioNTech Investor Day Presentation Deck
June 2022, 156 slides
  1. BioNTech
  2. Related Decks
  3. Investor Day Presentation Decks
innovation series | BioNTech
this slide presentation includes forward looking statements | BioNTech
safety information | BioNTech
safety information | BioNTech
agenda innovation series | BioNTech
welcome | BioNTech
the human immune system plays a central role in of human diseases | BioNTech
the tools we have developed for cancer will enable us to treat many diseases | BioNTech
taking from vision to reality | BioNTech
strong momentum built on two decades of innovation i clinical | BioNTech
today | BioNTech
advancing toward our long term vision | BioNTech
the approach to innovation | BioNTech
focused on five innovation pillars | BioNTech
| BioNTech
understanding and exploiting immunological mechanisms | BioNTech
focused on five innovation pillars | BioNTech
mutation based cancer heterogeneity the root cause of cancer therapy failure | BioNTech
mutations from cancer tissues are and of mutations are immunogenic when exploited as vaccine targets | BioNTech
exploiting the for personalized vaccination | BioNTech
acquisition of the patient tissue and blood samples sat a | BioNTech
identification of the patient cancer mutations cancer | BioNTech
prediction of mutations | BioNTech
individualized vaccine manufacturing | BioNTech
how do different types of induce cell responses and kill tumors | BioNTech
absolute frequency of genes selected for vaccination across trials the long tail of individual targets trials | BioNTech
focused on five innovation pillars | BioNTech
platform strategy technology agnostic innovation engine | BioNTech
technology broad built out of deep immunological a | BioNTech
technology each format is optimized for specific applications | BioNTech
technology sarna could induce higher and extended in and in expression compared to backbone optimized | BioNTech
technology amplifying could potentially be a vaccine strategy to induce potent immunity | BioNTech
technology we are exploring and sarna in multiple infectious disease programs | BioNTech
delivery formulations a diversified and rationally designed delivery platform for medicine hin spleen | BioNTech
delivery formulations a diversified and rationally designed delivery platform for medicine | BioNTech
focused on five innovation pillars | BioNTech
applications prediction covid variants monitoring and prediction | BioNTech
prediction drive individualized cancer medicine | BioNTech
prediction how do we identify predict and characterize | BioNTech
prediction individualized targets not all are created equal of | BioNTech
prediction genomic and drive our individualized target | BioNTech
prediction new based immune response model may improve accuracy of prediction based | BioNTech
covid variants monitoring and prediction reduction in time to detect new variants of concern by months be | BioNTech
covid variants monitoring and prediction predicted scores for immune escape and fitness prior correlate with in data | BioNTech
covid variants monitoring and prediction report june | BioNTech
focused on five innovation pillars | BioNTech
manufacturing and | BioNTech
diversified manufacturing across four distinct capabilities | BioNTech
expanding global manufacturing footprint | BioNTech
scaling up manufacturing | BioNTech
scaling up batch numbers | BioNTech
manufacturing innovation cycle time reduction with process | BioNTech
we are investing in global cell therapy infrastructures | BioNTech
a platform for localized and sustainable production | BioNTech
what is next in | BioNTech
focused on five innovation pillars to enable a new era of synthetic medicine | BioNTech
focused on five innovation pillars to enable a new era of synthetic medicine | BioNTech
platform innovation engine | BioNTech
new frontiers in new frontiers in infectious diseases infectious diseases | BioNTech
building on covid vaccine leadership to address global challenges | BioNTech
medical burden from infectious diseases is a growing global challenge top | BioNTech
covid vaccine validates our technology and paves the way for future products billion | BioNTech
and global collaboration programs in infectious diseases influenza | BioNTech
well prepared for the next phase of covid pandemic billion doses delivered to of countries and regions key drivers | BioNTech
granted for pediatric use low dose vaccination safely high protection | BioNTech
variant adapted vaccines next generation vaccine approaches aim to provide durable variant protection variant adapted and next generation vaccine approaches | BioNTech
variant adapted vaccines omicron consistent with simple superiority criterion for omicron modified vaccines participants a titer pug bivalent lug | BioNTech
variant adapted vaccines omicron consistent with super superiority criterion for monovalent omicron modified vaccine participants bivalent lug titer | BioNTech
variant adapted vaccines omicron rate exceeds criterion for omicron containing vaccines participants bivalent | BioNTech
variant adapted vaccines in participants without evidence of infection up to month after study vaccination immunogenicity subset a | BioNTech
variant adapted vaccines profile of variant vaccines overall similar to prototype vaccine | BioNTech
variant adapted vaccines omicron containing modified variant vaccine summary | BioNTech
variant adapted vaccines epidemiology changes quickly vaccine updates need to adapt with the pace of the virus | BioNTech
variant adapted vaccines omicron has more than all other variants combined | BioNTech
variant adapted vaccines and are now increasing in prevalence | BioNTech
variant adapted vaccines omicron and sequences are distinct from and | BioNTech
variant adapted vaccines omicron containing modified variant vaccines as dose elicit improved omicron neutralization response | BioNTech
omicron monovalent and bivalent boosters in mice substantially increase omicron neutralization responses to all omicron variants including and reference strain a | BioNTech
variant adapted vaccines omicron variant adapted vaccines increase omicron sub lineages ref titer ratio in mice | BioNTech
variant adapted vaccines a science driven preparedness strategy | BioNTech
pandemic preparedness an integrated faceted model for future pandemic preparedness a | BioNTech
malaria tuberculosis and remain endemic million cases million cases deaths million deaths deaths with | BioNTech
building an manufacturing network to address infectious diseases in and beyond | BioNTech
urgent need for next generation precision antibacterials million million effective the resistance by and severe bacterial infections | BioNTech
synthetic lysins a potentially ideal class of precision antibacterials fig | BioNTech
diverse and modular domain architecture allows flexibility in engineering | BioNTech
are highly potent and allow laser focused modulation | BioNTech
expanding opportunities in infectious diseases first in human vaccine trial starts expected in | BioNTech
a | BioNTech
time for a break | BioNTech
oncology pipeline | BioNTech
understanding and exploiting immunological mechanisms | BioNTech
oncology pipeline significant progress and expansion in | BioNTech
unique combination potential across platforms | BioNTech
cancer vaccines | BioNTech
vaccines for enabling potent targeting of cancers | BioNTech
driving continuous innovation with data | BioNTech
phase as and in combination with | BioNTech
vaccines are well suited for the early line setting | BioNTech
phase open label randomized trial in advanced melanoma gee | BioNTech
high medical need in the adjuvant treatment of stage high risk stage cancer ill | BioNTech
phase randomized trial watchful waiting in adjuvant cancer gee | BioNTech
phase trial of adjuvant in pancreatic adenocarcinoma is | BioNTech
substantial and durable cell expansion observed in immune responders after treatment gee | BioNTech
functional cells confirmed by in immune responders gee | BioNTech
immune response correlates with delayed recurrence in adjuvant gee | BioNTech
leveraging shared tumor associated antigens for cancer treatment | BioNTech
treatment options needed to address failure in advanced melanoma me | BioNTech
durable responses in a phase trial in advanced experienced melanoma experienced | BioNTech
long duration of clinical responses observed for patients receiving and combination with gee | BioNTech
tumor shrinkage observed in patients receiving or combination with a inhibitor | BioNTech
strong immunogenicity and promising clinical activity in phase merit | BioNTech
phase randomized trial in patients with anti melanoma is success measures | BioNTech
cancer vaccines near term milestones | BioNTech
protein therapeutics | BioNTech
combining blockade and conditional cell stimulation | BioNTech
first in human phase trial in heavily advanced solid tumors | BioNTech
initial results in dose show a manageable safety profile with most aes being grade or protein therapeutics | BioNTech
anti tumor activity phase dose part | BioNTech
clinical activity in patients with experienced relapsed refractory experienced | BioNTech
See More
BioNTech
Investor Day Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Vaccine
Cancer
Tumor
Manufacturing
Solid tumor
Cell therapy
Recent decks by BioNTech
Investor Presentation
August 2022
Results
August 2022
Results
March 2022
Investor Day
February 2022
See all presentations by BioNTech (12 decks)
Related decks
Immatics
Investor Presentation
November 2023
Mink Therapeutics
IPO
October 2021
Immix Biopharma
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
December 2023
Immix Biopharma
Investor Presentation
January 2024
Immix Biopharma
Investor Presentation
August 2023
Enochian Biosciences
Investor Presentation
January 2024
Legend Biotech
IPO
May 2020
Recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Results
March 2022
Investor Day
February 2022
Immatics
Investor Presentation
November 2023
Mink Therapeutics
IPO
October 2021
Immix Biopharma
Investor Presentation
August 2023
Immix Biopharma
Investor Presentation
December 2023
Immix Biopharma
Investor Presentation
January 2024
Immix Biopharma
Investor Presentation
August 2023
Enochian Biosciences
Investor Presentation
January 2024
Legend Biotech
IPO
May 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io